Swiss National Bank
ACET icon

Swiss National Bank’s Adicet Bio ACET Stock Holding History

Swiss National Bank’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,600
Closed -$240K – 2602
2023
Q1 		$240K Sell
2,600
-119
-4% -$14.9K ﹤0.01% 2630
2022
Q4 		$389K Buy
2,719
+75
+3% +$18.7K ﹤0.01% 2619
2022
Q3 		$602K Hold
2,644
– – ﹤0.01% 2515
2022
Q2 		$618K Buy
+2,644
New +$581K ﹤0.01% 2560

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Swiss National Bank's ACET Position: Q2 2023 in Review

Swiss National Bank sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 2,600 shares — an estimated $240K sold.

Swiss National Bank first reported a position in ACET in Q2 2022 and held it in 4 quarters. The position peaked at $618K in Q2 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

  • Swiss National Bank reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 2,600 Adicet Bio shares in Q2 2023, an estimated $240K.
  • Swiss National Bank first reported a position in Adicet Bio in Q2 2022 and held it in 4 quarters.
  • Swiss National Bank's Adicet Bio position peaked at $618K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.